In a 40-year-old male with a history of lung transplantation and diabetes mellitus presenting with cough and hemoptysis, with negative acid‑fast bacilli smear and HIV test, positive serum β‑D‑glucan and galactomannan, and bronchoalveolar lavage culture showing acute‑angle, dichotomously branching, septate hyphae, what is the diagnosis and appropriate treatment?

Diagnosis: Invasive Pulmonary Aspergillosis (IPA)

The diagnosis is invasive pulmonary aspergillosis, and the patient should be treated with voriconazole as first-line therapy given his lung transplant status. 1, 2

Diagnostic Reasoning

The clinical picture is pathognomonic for invasive aspergillosis in this lung transplant recipient:

• Microscopic findings: Acute-angle (45°), dichotomously branching, septate hyphae are the hallmark morphologic features of Aspergillus species, distinguishing them from mucormycosis (which shows broad, ribbon-like, aseptate hyphae with wide-angle branching at 90°)

• Biomarker profile: Both positive galactomannan and β-D-glucan support the diagnosis. In lung transplant recipients, BAL galactomannan has excellent diagnostic performance (sensitivity 85-100%, specificity 85-90% at cutoff 0.6-1.5) 2, 3. The combination of positive serum β-D-glucan and galactomannan increases diagnostic sensitivity to 83.3% 4

• Risk factors: Lung transplantation is the highest-risk solid organ transplant for IPA, with diabetes mellitus as an additional independent risk factor 3

Treatment Protocol for Lung Transplant Recipients

Primary therapy: Voriconazole is the recommended first-line agent 1, 2

Dosing and Monitoring

• Loading dose: 6 mg/kg IV q12h × 2 doses
• Maintenance: 4 mg/kg IV q12h, then transition to oral 200-300 mg q12h
• Critical: Therapeutic drug monitoring (TDM) is mandatory—voriconazole significantly increases calcineurin inhibitor levels (tacrolimus/cyclosporine), requiring dose reduction of immunosuppressants by 50-66% 2
• Monitor liver function tests closely, especially in transplant recipients
• Target voriconazole trough: 1-5.5 mcg/mL

Duration

Minimum 3 months or until complete resolution of IPA, whichever is longer 1

Alternative Agents (if voriconazole contraindicated or intolerant)

• Lipid formulation of amphotericin B (L-AmB) 3-5 mg/kg/day 1, 2
• Isavuconazole (fewer drug interactions than voriconazole)
• Posaconazole (delayed-release tablets or IV)

Combination Therapy Consideration

Voriconazole plus caspofungin showed survival benefit in solid organ transplant recipients with renal insufficiency or A. fumigatus infection 2. Consider adding caspofungin 70 mg loading dose, then 50 mg daily if:

• Severe disease with hemoptysis
• Renal dysfunction develops
• Inadequate response to monotherapy after 7 days

Critical Management Points

Immunosuppression adjustment: Reduce (but do not eliminate) immunosuppression when feasible to improve immune reconstitution while preventing rejection 1

Adjunctive bronchoscopic debridement: Consider for tracheobronchial involvement, especially with anastomotic complications common in lung transplant recipients 1

Serial galactomannan monitoring: Follow serum galactomannan weekly to assess therapeutic response and predict outcome 1

Common Pitfalls to Avoid

1. Drug-drug interactions: Failure to reduce calcineurin inhibitor doses leads to nephrotoxicity and neurotoxicity
2. Inadequate duration: Stopping therapy before 3 months or radiologic resolution results in relapse
3. Missing tracheobronchial disease: Lung transplant recipients require bronchoscopy to assess airway involvement, which may need inhaled amphotericin B (25-50 mg) as adjunctive therapy 1
4. Confusing with mucormycosis: The septate hyphae with acute-angle branching definitively rule out mucormycosis, which would require amphotericin B instead

Prophylaxis Consideration

After completing treatment, this patient should receive secondary prophylaxis with voriconazole 200 mg daily or inhaled amphotericin B (25-50 mg weekly) for at least 6 months post-transplant, given his high-risk status with diabetes 2